Grant: Master's Award: Canada Graduate Scholarships
University of Manitoba
$17,500.00
A NOVEL COMBINATION TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA
FY 2018-19
Summary
The body is made up of organs, which are made up of tissues, and tissues are made up of even smaller parts called cells. Cells in the body can divide to make more cells - like healing after an injury, and cells can also die. Cancer is a disease that occurs when cells divide without control and lose the ability to die; these cells can become a threat to other cells, tissues and organs and can lead to death. Thus, the aim of cancer research is to find treatments that kill cancer cells without hurting normal cells. Chronic lymphocytic leukemia (CLL) is a cancer of the blood that usually affects the elderly. There is currently no cure for most CLL patients and CLL cells can become resistant to treatment, making patients’ condition worse. One of the medications used to treat CLL is called ibrutinib; over time, side effects like infections, hypertension and bleeding prevent patients from continuing on ibrutinib.
Previous work in our laboratory showed that a medication/drug called KU55933, when combined with ibrutinib, can kill more cancer cells than ibrutinib alone. Another medicine in the same class as KU55933, called AZD0156, is being tested in patients with other cancers. We are currently testing whether the combination of AZD0156 with ibrutinib can improve CLL cell killing. We are also working on understanding why AZD0156 and KU55933 help kill more CLL cells when combined with ibrutinib. This research is important because ibrutinib and AZD0156 are already being used in the clinic; therefore, when we show that this new combination is more effective in killing CLL cells than ibrutinib alone, the combination could be implemented quickly to immediately benefit CLL patients.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406353
Name
Ehiremen Godsent
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A NOVEL COMBINATION TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Ataxia Telangiectasia Mutated (Atm); B-Cell Receptor; Bruton'S Tyrosine Kinase (Btk); Chemotherapy; Chronic Lymphocytic Leukemia (Cll); Combination Therapy; Dna Repair; Dna Repair Inhibitors; Ibrutinib; Synergy
Abstract
The body is made up of organs, which are made up of tissues, and tissues are made up of even smaller parts called cells. Cells in the body can divide to make more cells - like healing after an injury, and cells can also die. Cancer is a disease that occurs when cells divide without control and lose the ability to die; these cells can become a threat to other cells, tissues and organs and can lead to death. Thus, the aim of cancer research is to find treatments that kill cancer cells without hurting normal cells. Chronic lymphocytic leukemia (CLL) is a cancer of the blood that usually affects the elderly. There is currently no cure for most CLL patients and CLL cells can become resistant to treatment, making patients’ condition worse. One of the medications used to treat CLL is called ibrutinib; over time, side effects like infections, hypertension and bleeding prevent patients from continuing on ibrutinib.
Previous work in our laboratory showed that a medication/drug called KU55933, when combined with ibrutinib, can kill more cancer cells than ibrutinib alone. Another medicine in the same class as KU55933, called AZD0156, is being tested in patients with other cancers. We are currently testing whether the combination of AZD0156 with ibrutinib can improve CLL cell killing. We are also working on understanding why AZD0156 and KU55933 help kill more CLL cells when combined with ibrutinib. This research is important because ibrutinib and AZD0156 are already being used in the clinic; therefore, when we show that this new combination is more effective in killing CLL cells than ibrutinib alone, the combination could be implemented quickly to immediately benefit CLL patients.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ehiremen, Godsent
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~